<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596895</url>
  </required_header>
  <id_info>
    <org_study_id>UFJ2003-113</org_study_id>
    <nct_id>NCT00596895</nct_id>
  </id_info>
  <brief_title>Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer</brief_title>
  <official_title>Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Outcome Measures:&#xD;
&#xD;
      Decrease in rate of serum PSA rise&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
      Adherence to treatment regimens&#xD;
&#xD;
      Quality of life as assessed by FACT-P at baseline and at 12 months of treatment&#xD;
&#xD;
      Modulation of serum testosterone,isoflavone metabolites, and cholesterol&#xD;
&#xD;
      Estimated Enrollment: 27 Study Start Date: November 2003 Estimated Primary Completion Date:&#xD;
      February 2007 (Final data collection date for primary outcome measure)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Pretreatment evaluation included a complete medical history, physical examination&#xD;
           (including digital rectal examination), serum PSA, free/total testosterone, lipids,&#xD;
           serum isoflavone levels (genistein, daidzein, and equol), and assessment of quality of&#xD;
           life (Functional Assessment of Cancer Treatment-Prostate, FACT-P questionnaire).&#xD;
&#xD;
        -  Whole blood will be obtained prior to initiation of the study to assess for DNA&#xD;
           polymorphism.&#xD;
&#xD;
        -  Follow-up serum PSA levels to assess efficacy were obtained at 3, 6, 9, and 12 months&#xD;
           after initiation of treatment.&#xD;
&#xD;
        -  Medical history, physical examination, serum testosterone, lipids, isoflavone, and&#xD;
           quality of life were assessed at 6 and 12 months after initiation of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effect of soy protein/isoflavones serum PSA levels in patients previously treated with radical prostatectomy and external beam radiation therapy.</measure>
    <time_frame>Baseline, 3, 6, 9 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of soy protein/isoflavones on serum testosterone, isoflavone metabolites, and cholesterol. Assess the effect of soy protein/isoflavones on quality of life of these patients.</measure>
    <time_frame>Baseline, 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Biochemical Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isoflavone treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isoflavone</intervention_name>
    <description>Ingested 47 mg of isoflavone in three 8 oz servings per day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Soy Dream Enriched, Original or Vanilla, soy milk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Raising serum PSA profile after previous definitive therapy (e.g., radical&#xD;
             prostatectomy or external beam radiation therapy).&#xD;
&#xD;
          -  Life expectancy of at least one year and performance status of &lt;2 of Zubrod scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic or locally recurrent disease demonstrated on bone scan, computed tomography&#xD;
             or transrectal ultrasound, or be clinically symptomatic at the time of enrollment&#xD;
&#xD;
          -  No androgen deprivation therapy (ADT) or chemotherapy within 12 months of entry into&#xD;
             the study.&#xD;
&#xD;
          -  Known allergic reaction to milk or soy products were excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles J. Rosser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Shands</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>September 16, 2011</last_update_submitted>
  <last_update_submitted_qc>September 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Isoflavone, PSA, prostate cancer, recurrent, quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

